Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Taelman, Veerle
RITUXERA, NCT06003283: Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis	Recruiting	4	134	Europe	Rituximab, MabThera, Truxima, Ruxience, Rixathon	Universitaire Ziekenhuizen KU Leuven, Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)	Rheumatoid Arthritis	12/26	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Taelman, Veerle
RITUXERA, NCT06003283: Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis	Recruiting	4	134	Europe	Rituximab, MabThera, Truxima, Ruxience, Rixathon	Universitaire Ziekenhuizen KU Leuven, Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)	Rheumatoid Arthritis	12/26	12/26